Systemic therapy for lung cancer brain metastases: A rationale for clinical trials

ONCOLOGY

Volumn 22, Issue 2, 2008, Pages 168-178

  Oh, Yun ^a   Stewart, David J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOTEMUSTINE; GEFITINIB; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; LOMUSTINE; MITOLACTOL; MITOMYCIN; NAVELBINE; PACLITAXEL; PROCARBAZINE; TABLOID; TEMOZOLOMIDE; TENIPOSIDE; TIOGUANINE; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; DRUG TISSUE LEVEL; EARLY DIAGNOSIS; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; RISK ASSESSMENT; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; SYSTEMIC THERAPY; TUMOR GROWTH; TUMOR VASCULARIZATION; BRAIN TUMOR; CLINICAL TRIAL; LUNG TUMOR; METASTASIS; METHODOLOGY; PATHOLOGY; SKULL IRRADIATION; SMALL CELL CARCINOMA; STEREOTACTIC PROCEDURE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CLINICAL TRIALS AS TOPIC; CRANIAL IRRADIATION; HUMANS; LUNG NEOPLASMS; PROGNOSIS; STEREOTAXIC TECHNIQUES;

EID: 44949173137     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Johansson B: The physiology of the blood-brain barrier. Adv Exp Med Biol 274:25-39, 1990.
2. Gregoire N: The blood-brain barrier. J Neuroradiol 16:238-250, 1989.
3. Felgenhauer K: The blood-brain barrier redefined. J Neurol 233:193-194, 1986.
4. Shaprio WR, Shapiro JR: Principles of brain tumor chemotherapy. Semin Onc 13:56-59, 1986.
5. Zuelch K: Brain Tumors: Their Biology and Pathology, 3rd ed, pp 480-498. Berlin, Springer-Verlag, 1986.
6. Chen AM, Jahan TM, Jablons DM, et al: Risk of cerebral metastases and neurological death after pathological complete responses to neoadjuvant therapy for locally advanced non-small cell lung cancer: Clinical implications for the subsequent management of the brain. Cancer 109:1668-1675, 2007.
7. Stewart DJ: Human central nervous system pharmacology of antineoplastic agents: implications for the treatment of brain tumors, in Chatel M, Darcel E, Pecker J (eds): Brain Oncology, Biology, Diagnosis and Therapy, pp 387-395. Norwell, Mass; Kluwer; 1987.
8. Ushio Y, Posner J, Shapiro WR: Chemotherapy of experimental meningeal carcinomatosis. Cancer Res 37:1232-1237, 1977.
9. Siegal T, Sandbank U, Gabizon A, et al: Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. J Neurooncol 4:233-242, 1987.
10. Stewart PA, Hayakawa K, Farrell CL, et al: Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J Neurosurg 67:697-705, 1987.
11. Zagzag D, Goldenberg M, Brem S: Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: An experimental study in a rabbit brain-tumor model. AJR AM J Roentgenol 153:141-146, 1989.
12. Groothuis DR, Fischer JM, Vick NA, et al: Comparative permeability of different glioma models to horse-radish peroxidase. Cancer Treat Rep 65(suppl 2):13-18, 1981.
13. Feigin I, Allen LB, Lipkin L, et al: The endothelial hyperplasia of the cerebral blood vessels with brain tumors, and its sarcomatous transformation. Cancer 11:264-276, 1958.
14. Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416, 1998.
15. Dietrich WD, Busto R, Halley M, et al: The importance of brain temperature in alterations of the blood-brain barrier following cerebral ischemia. J Neuropathol Exp Neurol 49:486-497, 1990.
16. Zhang ZG, Zhang L, Jiang Q, et al: VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106:829-838, 2000.
17. Stewart DJ: A critique of the role of the blood-brain barrier in the chemotheapy of human brain tumors. J Neurooncol 20:121-139, 1994.
18. Walker MD, Hilton J: Nitrosourea pharmacodynamics in relation to the central nervous system. Cancer Treat Rep 60:725-728, 1976.
19. Eckhardt S, Csetenyi J, Horvath IP, et al: Uptake of labeled dianhydrogalactitol into human gliomas and nervous tissue. Cancer Treat Rep 61:841-847, 1977.
20. Ojima Y, Sullivan RD: Pharmacology of methotrexate in the human central nervous system. Surg Gynecol Obstet 125:1035-1040, 1967.
21. Hayakawa T, Ushio Y, Morimoto K, et al: Uptake of bleomycin by human brain tumors. J Neurol Neurosurg Psychiatry 39:341-349, 1976.
22. Simon G, Graul EH, Hundeshagen H: [Tracer-studies with radioactive-labelled cyclophosphamid in brain tumors.] Acta Neurochir (Wien) 13:441-456, 1965.
23. Stewart DJ, Richard M, Hugenholtz HN, et al: Cisplatin plus cytosine arabinoside in adults with malignant gliomas. J Neurooncol 2:29-34, 1984.
24. Stewart DJ, Grewaal D, Green R, et al: Human autopsy tissue distribution of menogaril and its metabolites. Cancer Chemother Pharmacol 32:373-378, 1993.
25. Stewart DJ, Grewaal D, Redmond D, et al: Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide. Cancer Chemother Pharmacol 32:368-372, 1993.
26. Stewart DJ, Lu K, Benjamin RS, et al: Concentrations of vinblastine in human intracerebral tumor and other tissues. J Neurooncol 1:139-144, 1983.
27. Stewart DJ, Zhengang G, Lu K, et al: Human tissue distribution of 4′-(9-acridinyl-amino)-methanesulfon-m-aniside (NSC 14159, AMSA). Cancer Chemother Pharmacol 12:116-119, 1984.
28. Stewart DJ, Rosenblum M, Luna M, et al: Disposition of methylglyoxyl bis (Guanylhydrazone) (MGBG, NSC-32946) in man. Cancer Chemother Pharmacol 7:31-35, 1981.
29. Stewart DJ, Benvenuto JA, Leavens M, et al: Penetration of 3-deazauridine into human brain, intracerebral tumor and cerebrospinal fluid. Cancer Res 39:4119-4122, 1979.
30. Stewart DJ, Grewaal D, Green R, et al: Adriamycin concentrations in human autopsy intracerebral and extracerebral tumors. J Neurooncology 7(suppl):S27, 1989.
31. Stewart DJ, Molepo M, Eapen L, et al: Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies. Int J Radiat Oncol Biol Phys 28:531-542, 1994.
32. Stewart DJ, O'Bryan M, Al-Sarraf M, et al: Phase II study of cisplatin in recurrent astrocytomas in adults. J Neurooncology 1:145-147, 1983.
33. Stewart DJ, Benjamin RS, Luna M, et al: Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 10:51-54, 1982.
34. Stewart DJ, Russell N, Quarrington A, et al: Cyclophosphamide, doxorubicin, vincristine, and dexamethasone in primary lymphoma of brain. Cancer Treat Rep 67:287-291, 1983.
35. Levin VA: A pharmacologic basis for brain tumor chemotherapy. Semin Oncol 2:57-61, 1975.
36. Blasberg RG, Groothuis DR: Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol 13:70-82, 1986.
37. Levin VA, Freeman-Dove W, Landahl D: Permeability characteristics of brain adjacent to tumors in rats. Arch Neurol 32:785-791, 1975.
38. Loo TL, Friedman E, Moore EC, et al: The pharmacologic disposition of N-(phospho-N-acetyl)-L-aspartate in humans. Cancer Res 40:86-90, 1980.
39. Stewart DJ, Leavens M, Friedman J, et al: Penetration of N-(phosphoacetyl)-L-aspartate in human central nervous system and intracerebral tumor. Cancer Res 40:3163-3166, 1980.
40. Stewart DJ, Leavens M, Maor M, et al: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42:2474-2479, 1982.
41. Stewart DJ, Mikhael NZ, Nair RC, et al: Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol 11:152-158, 1988.
42. Bonnem EM, Litterst CL, Smith FP: Platinum concentrations in human glioblastoma multiforme following the use of cisplatin. Cancer Treat Rep 66:1661-1663, 1982.
43. Stewart DJ, Molepo JM, Green R, et al: Factors affecting tumor cisplatin levels. Proc Am Assoc Cancer Res 31:180, 1990.
44. Gerosa M, Nicolato A, Foroni R, et al: Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg 102(suppl):75-80, 2005.
45. Plataniotis GA, Theofanopoulou M, Sotiriadou K, et al: The volume of brain metastases may be of prognostic significance in patients with non-small-cell lung cancer classified as RTOG-RPA classes 2 and 3 [comment]. Clin Oncol (R Coll Radiol) 18:85-86, 2006.
46. Antoniou D, Kyprianou K, Stathopoulos GP, et al: Response to radiotherapy in brain metastases and survival of patients with non-small cell lung cancer. Oncol Rep 14:733-736, 2005.
47. Kepka L, Cieslak E, Bujko K, et al: Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: The RTOG RPA intra-classes analysis. Acta Oncol 44:389-398, 2005.
48. Khuntia D, Brown P, Li J, et al: Wholebrain radiotherapy in the management of brain metastasis. J Clin Oncol 24:1295-1304, 2006.
49. Gulbas H, Erkal HS, Serin M: The use of recursive partitioning analysis grouping in patients with brain metastases from non-small-cell lung cancer. Jpn J Clin Oncol 36:193-196, 2006.
50. Gaspar LE, Scott C, Murray K, et al: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47:1001-1006, 2000.
51. Gaspar LE, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997.
52. Komaki R, Scott CB, Byhardt R, et al: Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 42:263-267, 1998.
53. Martin JJ, Kondziolka D; Indications for resection and radiosurgery for brain metastases. Curr Opin Oncol 17:584-587, 2005,
54. Jawahar A, Matthew RE, Minagar A, et al: Gamma knife surgery in the management of brain metastases from lung carcinoma: A retrospective analysis of survival, local tumor control, and freedom from new brain metastasis. J Neurosurg 100:842-847, 2004.
55. Lo SS, Chang EL, Suh JH: Stereotactic radiosurgery with and without whole-brain radiotherapy for newly diagnosed brain metastases [see comment]. Exp Rev Neurother 5:487-495, 2005.
56. Sheehan J, Kondziolka D, Flickinger J, et al: Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: Outcomes and prognostic factors. J Neurosurg 102(suppl):247-254, 2005.
57. Nakayama H, Tokuuye K, Komatsu Y, et al: Stereotactic radiotherapy for patients who initially presented with brain metastases from non-small cell carcinoma. Acta Oncol 43:736-739, 2004.
58. Chen JC, Petrovich Z, O'Day S, et al: Stereotactic radiosurgery in the treatment of metastatic disease to the brain. Neurosurgery 47:268-281 (incl discussion), 2000.
59. Petrovich Z, Yu C, Giannotta SL, et al: Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J Neurosurg 97(5 suppl):499-506, 2002.
60. Kong DS, Lee JI, Nam DH, et al: Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery. J Korean Med Sci 21:527-532, 2006.
61. Gupta T: Stereotactic radiosurgery for brain oligometastases: Good for some, better for all? Ann Oncol 16:1749-1754, 2005.
62. Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-1672, 2004.
63. Sneed PK, Lamborn KR, Forstner JM, et al: Radiosurgery for brain metastases: Is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 43:549-558, 1999.
64. Chidel M, Suh JH, Reddy CA, et al: Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 47:993-999, 2000.
65. Nieder C, Grosu AL, Astner S, et al: Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. Rad Oncol 1:19-25, 2006.
66. Gupta T: Stereotactic radiosurgery for brain oligometastases: Good for some, better for all? Ann Oncol 16:1749-1754, 2005.
67. Hu C, Chang EL, Hassenbusch SJ 3rd, et al: Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 106:1998-2004, 2006.
68. Sneed PK, Suh JH, Goetsch SJ, et al: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 53:519-526, 2002.
69. Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases a randomized controlled trial. JAMA 295:2483-2491, 2006.
70. McDermott MW, Sneed PK: Radiosurgery in metastatic brain cancer. Neurosurgery 57:S4-45-S4-53, 2005.
71. Manon R, O'Neill A, Knisely J, et al: Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: An Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 23:8870-8876, 2005.
72. Nieder C, Grosu Al, Astner S, et al: Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. Rad Oncol 1:19, 2006.
73. Schuette W: Treatment of brain metastases from lung cancer: Chemotherapy. Lung Cancer 45(suppl 2):S253-S257, 2004.
74. Tummarello D, Lippe P, Bracci R, et al: First line chemotherapy in patients with brain metastases from non-small and small cell lung cancer. Onc Rep 5:897-900, 1998.
75. Franciosi V, Coccini G, Michiara M, et al: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study [see comment]. Cancer 85:1599-1605, 1999.
76. Malacarne P, Santini A, Maestri A: Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 53:210-213, 1996.
77. Lee JS, Pisters KM, Komaki R, et al: Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: A preliminary report. Semin Oncol 24(4 suppl 12):S12-52-S12-55, 1997.
78. Cortes J, Rodriguez J, Aramendia JM, et al: Front-line paclitaxel/ cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 64:28-35, 2003.
79. Bernardo G, Cuzzoni Q, Strada MR, et al: First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: A phase II study. Cancer Invest 20:293-302, 2002.
80. Namba Y, Kijima T, Yokota S, et al: Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 6:123-128, 2004.
81. Ceresoli GL, Cappuzzo F, Gregorc F, et al: Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15:1042-1047, 2004.
82. Stemmler HJ, Weigert O, Krych M, et al: Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: A case report. Anticancer Drugs 16:747-749, 2005.
83. Choong NW, Dietrich S, Seiwert TY, et al: Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation. Nat Clin Pract Oncol 3:50-57, 2006.
84. Lai CSL, Boshoff C, Falzon M, et al: Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 61:91, 2006.
85. Kristjansen PE, Soelberg Sorensen P, Skov Hansen M, et al: Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen. Ann Oncol 4:579-583, 1993.
86. Seute T, Leffers P, Wilmink JT, et al: Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 24:2079-2083, 2006.
87. Lee JS, Murphy WK, Glisson BS, et al: Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol 7:916-922, 1989.
88. Ardizzoni A, Manegold C, Debruyne C: European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 9:143-50, 2003.
89. Korfel A, Oehm C, von Pawel J, et al: Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. A multicentre phase II study. Eur J Cancer 38:1724-1729, 2002.
90. Chou R, Chen A, Lau D: Complete response of brain metastases to irinotecan-based chemotherapy. J Clin Neurosci 12:242-245, 2005.
91. Fujita A, Fukuoka S, Takabatake H, et al: Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 59:291-295, 2000.
92. Abrey LE, Olson JD, Raizer JJ, et al: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53:259-265, 2001.
93. Giorgio CG, Giuffrida D, Pappalardo A, et al: Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: Phase II study. Lung Cancer 50:247-254, 2005.
94. Dziadziuszko R, Ardizzoni A, Postmus PE, et al: Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: A phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 39:1271-1276, 2003.
95. Christodoulou C, Bafaloukos D, Linardou H, et al: Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: A Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 71:61-65, 2005.
96. Cotto C, Berille J, Souquet PJ, et al: A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 32A:69-71, 1996.
97. Khayat D, Giroux B, Berille J, et al: Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 12:414-420, 1994.
98. Kaba SE, Kyritsis AP, Hess K, et al: TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol 15:1063-1070, 1997.
99. Minotti V, Crino L, Meacci ML, et al: Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 20:93-98, 1998.
100. Ushio Y, Arita N, Hayawaka T, et al: Chemotherapy of brain metastases from lung carcinoma: A controlled randomized study. Neurosurgery 28:201-205, 1991.
101. Harita S, Mizuta A, Kuyama S, et al: Long-term survival following concurrent chemoradiotherapy in patients with non-small-cell lung cancer with concomitant brain metastases only. Int J Clin Oncol 10:63-68, 2005.
102. Pronzato P, Bruna F, Neri E, et al: Radiotherapy plus carboplatin and teniposide in patients with brain metastases from non small cell lung cancer. Anticancer Res 15:517-519, 1995.
103. University of Alberta Drug Bank Database, 2006.
104. Nugent JL, Bunn PA Jr, Matthews MJ, et al: CNS metastases in small cell bronchogenic carcinoma: Increasing frequency and changing pattern with lengthening survival. Cancer 44:1885-1893, 1979.
105. Bunn PA Jr, Nugent JL, Matthews MJ: Central nervous system metastases in small cell bronchogenic carcinoma. Semin Oncol 5:314-322, 1978.
106. Komaki R, Cox JD, Stark R: Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: Correlation with survival. Int J Radiat Oncol Biol Phys 9:1467-1470; 1983.
107. Seute T, Leffers P, Wilmink IT, et al: Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 24:2079-2083, 2006.
108. Sorensen JB, Hansen HH, Hansen M, et al: Brain metastases in adenocarcinoma of the lung: Frequency, risk groups, and prognosis. J Clin Oncol 6:1474-1480, 1988.
109. Barlesi F, Jacot W, Astoul P, et al: Second-line treatment for advanced non-small cell lung cancer: A systematic review. Lung Cancer 51:159-172, 2006.
110. Mandybur TI: Intracrainal hemorrhage caused by metastatic tumors. Neurology 27:650-655, 1977.
111. Bitoh S, Hasegawa H, Ohtsuki H, et al: Cerebral neoplasms initially presenting with massive intracerebral hemorrhage. Surg Neurol 22:57-62, 1984.
112. Maor MH, Dubey P, Tucker SL, et al: Stereotactic radiosurgery for brain metastases: results and prognostic factors. Int J Cancer 90:157-162, 2000.
113. Noel G, Medioni J, Valery CA, et al: Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancer. Lung Cancer 41:333-343, 2003.
114. Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomized trial. Lancet 363:1665-1672, 2004.
115. Suzuki H, Toyoda S, Muramatus M, et al: Spontaneous haemorrhage into metastatic brain tumours after stereotactic radiosurgery using a linear accelerator. J Neurol Neurosurg Phsychaitry 74:908-912, 2003.
116. Licata C, Turazzi S: Bleeding cerebral neoplasm with symptomatic hematoma. J Neurosurg Sci 47:201-210, 2003.
117. Srivastava G, Rana V, Allen S, et al: The risk of spontaneous hemorrhage from non-small cell lung cancer brain metastases. Submitted 2007.
118. Kinch MS, Moore MB, Harpole DH Jr: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613-618, 2003.